Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
International Waldenstrom's Macroglobulinemia Foundation (IWMF) 2019 Forum
June 07 - 09, 2019; Philadelphia, Pennsylvania
June 07 - 09, 2019Philadelphia, Pennsylvania
IWMF 2019New Lymphoma Drugs Build on BTK Inhibitor SuccessLife expectancy for patients with Waldenstrom's macroglobulinemia has improved considerably in the past decade, and new treatments on the horizon could mean that trend continues.
Patience Needed: WM Is Incurable, but Survival Is LongManagement of the rare lymphoma Waldenstrom's macroglobulinemia (WM) takes patience and practice to maximize longevity and
keep symptoms at bay over the long haul.
Medscape Medical News, May 23, 2018
New Drugs Poised to Expand Treatment Horizons in WMNew drug combinations and pathways continue to be mined in an effort to expand treatment horizons for control of a rare lymphoma
and extend quality of life for patients over many years to come.
